Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Specific antibody of coronavirus, or antigen-binding fragment of specific antibody

A technology that combines fragments and coronaviruses. It is applied in the direction of antibodies, antiviral agents, and antiviral immunoglobulins. It can solve the problems of virus genome sequence mutations and loss of protective effects of mutant viruses.

Active Publication Date: 2020-12-25
SHANGHAI PUBLIC HEALTH CLINICAL CENT
View PDF5 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Although the antibodies currently reported by other teams have good neutralizing ability to the tested SARS-CoV-2 virus strains, due to the SARS-CoV-2 virus It is an RNA virus, and the genome sequence of the virus is prone to mutations during the spread of the epidemic
When the non-conserved region recognized by these antibodies is mutated to produce a new circulating strain, the antibody will lose its protective effect against the mutant virus

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Specific antibody of coronavirus, or antigen-binding fragment of specific antibody
  • Specific antibody of coronavirus, or antigen-binding fragment of specific antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0051] Example 1: Screening and detection of specific antibodies to coronavirus

[0052] The inventor conducted a pseudovirus assay on the plasma of patients with novel coronavirus pneumonia (followed up two weeks after recovery and discharge) admitted to the inventor's unit (Shanghai Public Health Clinical Center) from January 20, 2020 to February 26, 2020. And experimental screening, it was found that the serum of one of the mild patients had a strong neutralizing activity against the SARS-CoV-2 pseudovirus. With the written consent of the ethics committee of the inventor's unit and the patient himself, his peripheral blood was drawn for research.

[0053] 1. Sorting of peripheral blood memory B cells

[0054] 1) Separation of peripheral blood lymphocytes: extract the convalescent peripheral blood of the above-mentioned patients and mix it with an equal amount of normal saline, then use Lymphoprep (Stemcell Technologies, Cat. No. 07851) to separate peripheral blood lymphocyt...

Embodiment 2

[0086] This example describes a method that can be used to treat diseases caused by coronaviruses including SARS-CoV-2 by administering the coronavirus-specific monoclonal antibodies of the present application.

[0087] Although specific methods, dosages and modes of administration have been provided, it will be understood by those skilled in the art that changes may be made without substantially affecting the treatment. Based on the teachings disclosed herein, coronavirus infection can be treated or prevented by administering a therapeutically effective amount of one or more of the antibodies described herein, thereby reducing or eliminating coronavirus infection.

[0088] The specific application method is as follows:

[0089]1) Screening of subjects: First, subjects are screened to determine whether they are infected with coronaviruses such as SARS-CoV-2. The method for screening SARS-CoV-2 infection can use respiratory specimen nucleic acid detection combined with clinica...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a specific antibody of coronavirus or an antigen-binding fragment of the specific antibody, a nucleic acid molecule encoding the antibody or the antigen-binding fragment thereof, a vector comprising the nucleic acid molecule, a host cell comprising the vector, an application of the antibody or the antigen-binding fragment thereof in the preparation of drugs for treating orpreventing diseases caused by coronavirus, and an application of the antibody or the antigen-binding fragment thereof in detection products. The antibody of coronavirus and the antigen-binding fragment of the antibody, which are obtained by inventors through the B cell in-vitro monoclonal culture and high-throughput antibody screening technology, have strong binding capacity and neutralizing capacity on the SARS-CoV-2 virus, can recognize and bind the S1 protein of the SARS-CoV-2 virus and the RBD of the S1 protein, and have very strong affinity. Therefore, it can be speculated that the antibody of coronavirus and the antigen binding fragment of the antibody possibly have binding capacity and neutralizing capacity on other coronaviruses and coronaviruses possibly occurring in the future,and thereby the antibody of coronavirus and the antigen binding fragment of the antibody have good clinical application prospects in the future.

Description

technical field [0001] The present invention relates to a coronavirus-specific antibody or an antigen-binding fragment thereof, a nucleic acid molecule encoding the antibody or an antigen-binding fragment thereof, a vector comprising the nucleic acid molecule, a host cell comprising the vector, and the antibody or an antigen-binding fragment thereof The application of the fragments in the preparation of drugs for the treatment or prevention of diseases caused by coronaviruses, as well as the application in the detection of products, belongs to the field of biomedicine. Background technique [0002] Novel coronavirus pneumonia (2019-nCOV) is an acute respiratory infectious disease caused by a new type of coronavirus, SARS-COV-2. The virus is highly transmissible and can be transmitted through the respiratory tract, contact and other channels. Since the outbreak in December 2019, it has spread to all parts of the world, forming a worldwide pandemic. As of July 1, 2020, the SA...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/10C12N15/13A61K39/42A61P31/14G01N33/577G01N33/569
CPCC07K16/10A61P31/14G01N33/577G01N33/56983A61K2039/505C07K2317/565C07K2317/76C07K2317/92G01N2333/165G01N2469/10
Inventor 黄竞荷吴凡刘梅
Owner SHANGHAI PUBLIC HEALTH CLINICAL CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com